论文部分内容阅读
目的:研究胃癌组织中miR-29的表达情况及其与临床病理特征和预后的关系。方法:收集2005年至2010年中国人民解放军第324医院收治的进展期胃癌113例患者的手术标本,定量PCR检测胃癌组织及癌旁组织内miR-29的表达,并分析其与胃癌患者临床病理特征的关系。结果:胃癌组织内miR-29的表达显著低于对应的癌旁组织(2.62±1.17vs3.14±1.70,P=0.006),伴淋巴结转移的胃癌患者低表达miR-29百分率显著高于无淋巴结转移组(58.9%vs32.5%,P=0.007),miR-29低表达胃癌患者中位生存率显著低于miR-29高表达者(33.0vs44.0个月,P=0.013)。结论:胃癌组织低表达miR-29,miR-29有可能成为胃癌的预后判断指标及治疗靶标。
Objective: To investigate the expression of miR-29 in gastric carcinoma and its relationship with clinicopathological features and prognosis. Methods: The surgical specimens of 113 patients with advanced gastric cancer admitted from the 324th Hospital of Chinese People’s Liberation Army from 2005 to 2010 were collected. The expression of miR-29 in gastric cancer tissue and paracancerous tissues was detected by quantitative PCR. Characteristics of the relationship. Results: The expression of miR-29 in gastric cancer tissues was significantly lower than that in corresponding paracancerous tissues (2.62 ± 1.17 vs 3.14 ± 1.70, P = 0.006). The percentage of low-expressed miR-29 in gastric cancer with lymph node metastasis was significantly higher than that in non-lymph node (58.9% vs 32.5%, P = 0.007). The median survival of patients with low expression of miR-29 was significantly lower than that of patients with high expression of miR-29 (33.0 vs 44.0 months, P = 0.013). Conclusion: The low expression of miR-29 and miR-29 in gastric cancer may be prognostic indicators and therapeutic targets for gastric cancer.